AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30565198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no auditory stimuli provided)
Number of subjects: 33
Study 30565198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic neurofeedback
Number of subjects: 33
Study 28487140 — intervention group
Group type: EXPERIMENTAL
Intervention: GLASS program (peer-led physical activity and object control skill intervention)
Number of subjects: 224
Study 25163397 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus zoledronic acid (4 mg intravenously 4-weekly)
Number of subjects: 30
Study 25163397 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg daily)
Number of subjects: 30
Study 24113263 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-only condition
Number of subjects: 635
Study 24113263 — intervention group
Group type: COMPARATOR
Intervention: No nutritional information
Number of subjects: 635
Study 24113263 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie amounts in 'traffic lights'
Number of subjects: 635
Study 24113263 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie, fat, sodium, and sugar shown in 'traffic lights'
Number of subjects: 635
Study 21816918 — intervention group
Group type: EXPERIMENTAL
Intervention: EN stent-assisted coiling
Number of subjects: 39
Study 19118302 — intervention group
Group type: COMPARATOR
Intervention: Selective Oropharyngeal Decontamination (SOD)
Number of subjects: 5939
Study 19118302 — intervention group
Group type: COMPARATOR
Intervention: Selective Digestive Tract Decontamination (SDD)
Number of subjects: 5939
Study 19118302 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care
Number of subjects: 5939
Study 19260188 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive devices and community-based services
Number of subjects: 147
Study 19260188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention indicated by occupational therapist
Number of subjects: 147
Study 19260188 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and instruction on mobility-related issues
Number of subjects: 147
Study 19260188 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and instruction on personal care-related issues
Number of subjects: 147
Study 19260188 — intervention group
Group type: EXPERIMENTAL
Intervention: Application procedure for assistive devices and community-based services
Number of subjects: 147
Study 15322962 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy (including continued psychoeducation)
Number of subjects: 75
Study 15322962 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management with methylphenidate plus psychoeducation
Number of subjects: 75
Study 15322962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (behaviour therapy + medical management)
Number of subjects: 75
Study 10778024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed feedback intervention
Number of subjects: 0
Study 10778024 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9060881 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride, 8.4 g/day orally for 2 weeks
Number of subjects: 0
Study 9060881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9060881 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride, 8.4 g/day orally after 2 weeks of treatment
Number of subjects: 0
Study 9060881 — intervention group
Group type: COMPARATOR
Intervention: Normocholesterolemic control subjects
Number of subjects: 0
Study 9060881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic patients
Number of subjects: 0
Study 8101512 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 58
Study 8101512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 3069250 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic regimen 1
Number of subjects: 0
Study 3069250 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic regimen 2
Number of subjects: 0
Study 31253188 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning
Number of subjects: 3
Study 31253188 — intervention group
Group type: EXPERIMENTAL
Intervention: blended learning
Number of subjects: 3
Study 31253188 — intervention group
Group type: COMPARATOR
Intervention: waiting control group
Number of subjects: 3
Study 28292497 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 209
Study 28292497 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose monitoring
Number of subjects: 209
Study 28292497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both monitoring methods
Number of subjects: 209
Study 25527749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phenolic olive oil (20 mL daily for 6 weeks)
Number of subjects: 69
Study 25527749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phenolic olive oil (20 mL daily for 6 weeks)
Number of subjects: 69
Study 23772999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 μg/kg body weight
Number of subjects: 148
Study 23772999 — intervention group
Group type: COMPARATOR
Intervention: Lindane lotion 1% (two applications with a 1-week interval)
Number of subjects: 148
Study 21944667 — intervention group
Group type: EXPERIMENTAL
Intervention: BTP levels
Number of subjects: 865
Study 21944667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels
Number of subjects: 865
Study 21944667 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 865
Study 21944667 — intervention group
Group type: EXPERIMENTAL
Intervention: mGFR
Number of subjects: 865
Study 21944667 — intervention group
Group type: EXPERIMENTAL
Intervention: All markers (including eGFR)
Number of subjects: 865
Study 18706751 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 193
Study 18706751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 20100317 — intervention group
Group type: EXPERIMENTAL
Intervention: EFICAR exercise program (3 month supervised progressive exercise program with aerobic and strength components, followed by 9 months linked with community resources)
Number of subjects: 600
Study 20100317 — intervention group
Group type: EXPERIMENTAL
Intervention: EFICAR exercise program
Number of subjects: 600
Study 20100317 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimized treatment according to European Society of Cardiology guidelines)
Number of subjects: 600
Study 16269588 — intervention group
Group type: EXPERIMENTAL
Intervention: FTI of 8fr/cb projections (IP)
Number of subjects: 34
Study 16269588 — intervention group
Group type: EXPERIMENTAL
Intervention: FTI of 8fr/cb reconstructed slices (IS)
Number of subjects: 34
Study 16269588 — intervention group
Group type: COMPARATOR
Intervention: Raw 8fr/cb acquisition (R8)
Number of subjects: 34
Study 16269588 — intervention group
Group type: COMPARATOR
Intervention: Raw 16fr/cb acquisition (R16)
Number of subjects: 34
Study 16269588 — intervention group
Group type: EXPERIMENTAL
Intervention: FTI (IP)
Number of subjects: 34
Study 16269588 — intervention group
Group type: EXPERIMENTAL
Intervention: FTI (IS)
Number of subjects: 34
Study 16269588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine display fluidity (IP)
Number of subjects: 34
Study 16269588 — intervention group
Group type: COMPARATOR
Intervention: Cine display fluidity (R16)
Number of subjects: 34
Study 11943442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 0
Study 11943442 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0
Study 11943442 — intervention group
Group type: COMPARATOR
Intervention: Recruitment strategies
Number of subjects: 0
Study 11943442 — intervention group
Group type: COMPARATOR
Intervention: Recruitment cost
Number of subjects: 0
Study 11943442 — intervention group
Group type: COMPARATOR
Intervention: Staff time devoted to recruitment
Number of subjects: 0
Study 9601621 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NGmethylarginine hydrochloride (546C88) 6 mg/kg i.v. over 15 min
Number of subjects: 18
Study 9601621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose) i.v. over 15 min
Number of subjects: 18
Study 7978178 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-xylitol 35% (1:1)
Number of subjects: 24
Study 7978178 — intervention group
Group type: COMPARATOR
Intervention: Glucose 40%
Number of subjects: 24
Study 2645013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative antibiotics (group P): 3 intravenous doses of 500 mg metronidazole plus 1 g cephazolin.
Number of subjects: 700
Study 2645013 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative antibiotics (group T): 3 intravenous doses of 500 mg metronidazole plus 1 g cephazolin.
Number of subjects: 700
Study 2645013 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI >= 26).
Number of subjects: 700
Study 2645013 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin patients (BMI < 24).
Number of subjects: 700
Study 1217975 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (Akineton) after slow intravenous application
Number of subjects: 10
Study 1217975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31683172 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty ward unit
Number of subjects: 118
Study 31683172 — intervention group
Group type: COMPARATOR
Intervention: ICU
Number of subjects: 118
Study 29544158 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week ACE Overcomers program (faith-based or secular)
Number of subjects: 92
Study 27442309 — intervention group
Group type: EXPERIMENTAL
Intervention: PHR-delivered ACP framework
Number of subjects: 50
Study 27442309 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices
Number of subjects: 50
Study 24595631 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) therapy
Number of subjects: 1479
Study 24595631 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-providing (IP) therapy
Number of subjects: 1479
Study 24595631 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1479
Study 22038315 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-water bath (WWB) with tap water at 41°C for 10 minutes
Number of subjects: 7
Study 22038315 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-water bath (WWB) with ISCO(2) (bath additive with inorganic salts and carbon dioxide) at 41°C for 10 minutes
Number of subjects: 7
Study 22038315 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-water bath (WWB) with ISCO(2) at 41°C for 10 minutes
Number of subjects: 7
Study 19388619 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 23
Study 19388619 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 23
Study 19388619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 23
Study 17093912 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy in one fraction
Number of subjects: 44
Study 17093912 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy in five fractions
Number of subjects: 44
Study 17093912 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both interventions)
Number of subjects: 44
Study 15631531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg plus statin
Number of subjects: 1861
Study 15631531 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy (lovastatin or pravastatin 10, 20 or 40 mg, simvastatin or atorvastatin 10, 20, 40 or 80 mg)
Number of subjects: 1861
Study 11476015 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Extra Whitening dentifrice
Number of subjects: 672
Study 11476015 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed tartar control baking soda peroxide whitening dentifrice
Number of subjects: 672
Study 11476015 — intervention group
Group type: COMPARATOR
Intervention: Regular dentifrice control
Number of subjects: 672
Study 11476015 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Extra Whitening dentifrice and Marketed tartar control baking soda peroxide whitening dentifrice
Number of subjects: 672
Study 9734786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 62
Study 9734786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 8037485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day) for 2 years
Number of subjects: 112
Study 8037485 — intervention group
Group type: COMPARATOR
Intervention: No tamoxifen administration
Number of subjects: 112
Study 2564753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.8 +/- 0.2 mg)
Number of subjects: 30
Study 2564753 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 2564753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.6-1.0 mg iv)
Number of subjects: 30
Study 31476924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 50 mg/d
Number of subjects: 28
Study 31476924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30568596 — intervention group
Group type: EXPERIMENTAL
Intervention: WB-EMS training
Number of subjects: 18
Study 30568596 — intervention group
Group type: COMPARATOR
Intervention: Traditional strength training
Number of subjects: 18
Study 26406217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strengthening group (n = 15)
Number of subjects: 30
Study 26406217 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (n = 15)
Number of subjects: 30
Study 25672386 — intervention group
Group type: COMPARATOR
Intervention: No treatment, first bonding (control)
Number of subjects: 75
Study 25672386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with aluminum oxide
Number of subjects: 75
Study 25672386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting + silane
Number of subjects: 75
Study 25672386 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating + silane
Number of subjects: 75
Study 25672386 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicatization performed in a laboratory (Rocatec system)
Number of subjects: 75
Study 22980542 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel at a concentration of 250 μg ml(‐1)
Number of subjects: 7
Study 22980542 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone from the iliac crest
Number of subjects: 7
Study 22980542 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel at a concentration of 50 μg ml(‐1)
Number of subjects: 7
Study 22980542 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel
Number of subjects: 7
Study 20492060 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued nursing intervention guided by chronotherapeutics
Number of subjects: 0
Study 20492060 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medicine (control group)
Number of subjects: 0
Study 18384419 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (ACh)
Number of subjects: 18
Study 18384419 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 18
Study 18384419 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 18
Study 18384419 — intervention group
Group type: COMPARATOR
Intervention: Local heating (44 degrees C)
Number of subjects: 18
Study 16630937 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablet 75,000 SQ-T
Number of subjects: 855
Study 16630937 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablet 75,000 SQ-T (subgroup analysis)
Number of subjects: 855
Study 16630937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 855
Study 12109918 — intervention group
Group type: EXPERIMENTAL
Intervention: RTU dobutamine
Number of subjects: 58
Study 12109918 — intervention group
Group type: COMPARATOR
Intervention: Admix dobutamine
Number of subjects: 58
Study 10073871 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 0
Study 8520804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg)
Number of subjects: 18
Study 8520804 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.2 mg) with Pantoprazole (40 mg)
Number of subjects: 18
Study 8520804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2322635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam SR tablet while fasting
Number of subjects: 21
Study 2322635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam SR tablet immediately after a standardized breakfast
Number of subjects: 21
Study 2322635 — intervention group
Group type: COMPARATOR
Intervention: 1 mg alprazolam conventional tablet while fasting
Number of subjects: 21
Study 377897 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2-gel (0.25 mg PGE2)
Number of subjects: 20
Study 377897 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (without PGE2)
Number of subjects: 20
Study 31915046 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Danhong Injection
Number of subjects: 336
Study 31915046 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Danhong Injection
Number of subjects: 336
Study 31915046 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 336
Study 29789611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at beta frequencies during a visual temporal bisection task
Number of subjects: 20
Study 29789611 — intervention group
Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) at alpha frequencies during a visual temporal bisection task
Number of subjects: 20
Study 27659566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10942
Study 27659566 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10942
Study 26013142 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually performed manipulations
Number of subjects: 54
Study 26013142 — intervention group
Group type: COMPARATOR
Intervention: Electromechanical manipulations
Number of subjects: 54
Study 23039340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol chocolate
Number of subjects: 10
Study 23039340 — intervention group
Group type: COMPARATOR
Intervention: Control chocolate
Number of subjects: 10
Study 20520602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine
Number of subjects: 52
Study 20520602 — intervention group
Group type: COMPARATOR
Intervention: D‐amphetamine (30 mg)
Number of subjects: 52
Study 20520602 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 52
Study 20520602 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 52
Study 20520602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 18391324 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Mounted Display (HMD)
Number of subjects: 100
Study 18391324 — intervention group
Group type: COMPARATOR
Intervention: No Head Mounted Display (non-HMD)
Number of subjects: 100
Study 16766594 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg L-AmB every other day (arm A)
Number of subjects: 132
Study 16766594 — intervention group
Group type: COMPARATOR
Intervention: No systemic antifungal prophylaxis (arm B)
Number of subjects: 132
Study 14651419 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 14651419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10807830 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented-support (AS) group, n = 54
Number of subjects: 108
Study 10807830 — intervention group
Group type: COMPARATOR
Intervention: Basic-support (BS) group, n = 54
Number of subjects: 108
Study 9257763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of isepamicin (1-g dose)
Number of subjects: 18
Study 9257763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of isepamicin (1-g dose)
Number of subjects: 18
Study 9257763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of isepamicin
Number of subjects: 18
Study 9257763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of isepamicin
Number of subjects: 18
Study 9257763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion and intramuscular injection of isepamicin
Number of subjects: 18
Study 8099791 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT in a rested condition
Number of subjects: 40
Study 8099791 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT plus 40.5 hours of total sleep deprivation
Number of subjects: 40
Study 8099791 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sleep deprivation
Number of subjects: 40
Study 8099791 — intervention group
Group type: COMPARATOR
Intervention: Placebo in a rested condition
Number of subjects: 40
Study 8099791 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT plus sleep deprivation
Number of subjects: 40
Study 8099791 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT alone
Number of subjects: 40
Study 8099791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation alone
Number of subjects: 40
Study 2433016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP), vincristine, and bleomycin or CDDP and 5‐fluorouracil (5‐FU) infusion
Number of subjects: 191
Study 2433016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and 5‐FU infusion combination
Number of subjects: 191
Study 2433016 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologically complete responders who completed local radiation therapy
Number of subjects: 191
Study 2433016 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response both clinically and histologically
Number of subjects: 191
Study 2433016 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced nodal disease
Number of subjects: 191
Study 30354362 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with complete cyclosporine withdrawal
Number of subjects: 115